rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Champions Oncology, Inc.

CSBR · Nasdaq

Health CareBiotechnologyNot moving yet

CSBR stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 16.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 39
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
25 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders25+4 on the quarter
New · exited5 · 1
Reported value$36.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BATTERY MANAGEMENT CORP.unchanged · filed 14 Aug 20262,421,673$14.9M00.0%
NEA Management Company, LLCunchanged · filed 14 Aug 20261,713,720$10.6M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026301,353$1.9M+1,833+0.6%
TOCQUEVILLE ASSET MANAGEMENT L.P.reduced · filed 10 Aug 2026295,658$1.8M-24,016−7.5%
MORGAN STANLEYreduced · filed 13 Aug 2026235,400$1.5M-6,900−2.8%
BANK OF AMERICA CORPadded · filed 14 Aug 2026214,058$1.3M+192,225+880.4%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026139,039$856K-6,500−4.5%
BlackRock, Inc.added · filed 7 Aug 2026129,848$800K+5,948+4.8%
Mink Brook Asset Management LLCunchanged · filed 14 Aug 2026111,338$686K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202676,300$470K-877−1.1%
31 Mar 2023 – 30 Jun 2026
192531Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Joel Ackerman Company insiderDirector · last 15 Oct 202610 · 1
Daniel Newman Mendelson Company insiderDirector · last 5 Nov 202530 · 2
David Sidransky Company insiderDirector · last 5 Nov 20250 · 0
Philip P. Breitfeld Company insiderDirector · last 5 Nov 20250 · 1
Scott R. Tobin Company insiderDirector, 10% owner · last 5 Nov 20250 · 0
Robert Lawrence Brainin Company insiderCEO · last 16 Jul 20250 · 0
Brady Davis Company insiderPresident · last 9 Oct 20230 · 0
Ronnie Morris Company insiderCEO · last 17 Mar 202316 · 1
Abba David Poliakoff Company insiderDirector · last 19 Jan 20210 · 0
Jesse Feldman Company insider10% owner · last 11 Mar 20201 · 0
Nea 14 Gp, Ltd Company insider10% owner · last 6 Mar 20200 · 1
David Barry Miller Company insiderVice President, Finance · last 21 Jul 20160 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 30 Apr 202648.0%
Operating profit marginFY 2026 · to 30 Apr 2026-1.9%
Free cash flow marginFY 2026 · to 30 Apr 2026-8.5%
Return on capital employedFY 2026 · to 30 Apr 2026-16.1%
Research spendFY 2026 · to 30 Apr 202615.3%
Share count trendFY 2026 · to 23 Jul 20260.0%
Cash and equivalentsFY 2026 · to 30 Apr 2026$4.9M
Free cash flowFY 2026 · to 30 Apr 2026−$5.0M

Analyst forecasts

No analyst forecasts yet.